Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
We describe the currently enrolling Phase 3 single-arm COMMUTE-a (NCT04861259) and COMMUTE-p (NCT04958265) trials evaluating crovalimab (crova), a novel C5 inhibitor (C5i), in acute haemolytic uraemic syndrome (aHUS). Crova, with subcutaneous (SC) administration every 4 weeks (Q4W) (or every 2 weeks [Q2W] in patients [pts] <20 kg with aHUS), and the potential for self-administration, could reduce treatment burden vs other C5is in aHUS. Pt preference data from the global, randomised, Phase 3 COMMODORE 1 (NCT04432584) and 2 (NCT04434092) trials (Röth EHA 2023, Scheinberg EHA 2023) evaluating crova in pts with paroxysmal nocturnal haemoglobinuria (PNH), another complement-mediated disorder, are reported.
COMMODORE 1 and 2 enrolled C5i-experienced and C5i-naive pts with PNH, respectively. Pts were randomised to receive crova (weight-based tiered dosing regimen: loading doses and SC Q4W maintenance) or eculizumab (ecu; 900 mg IV Q2W) over 24 weeks. All pts then received crova if continuing on trial. Treatment preference was assessed in adult pts using the validated Patient Preference Questionnaire (PPQ) after 17 weeks of crova treatment in C5i-experienced pts randomised to crova in COMMODORE 1 and in pts initially randomised to ecu who switched to crova at Week (W)25 in COMMODORE 1 and 2.
COMMUTE-a is enrolling pts with aHUS aged ≥12 years [y] (N≈80) and COMMUTE-p is enrolling pts with aHUS aged ≥28 days to <18 y (N≈45), both in 3 cohorts (Figure 1): (1) Naive, (2) Switch, (3) C5 polymorphism (SNP) cohort in COMMUTE-a: pts with known C5 SNPs; pretreated cohort in COMMUTE-p: pts previously treated with and discontinued ecu or ravu (with or without known C5 SNPs).
In both COMMUTE studies, pts receive weight-based tiered crova dosing: IV and SC loading doses, and SC Q4W maintenance (or Q2W if <20 kg). The primary efficacy objective of both studies is to assess the proportion of C5i-naive pts with complete thrombotic microangiopathy response from baseline to W25. Secondary efficacy endpoints include change from baseline in dialysis requirement status and estimated glomerular filtration rate. Treatment preference will be assessed using the PPQ in pts aged ≥12 y and in caregivers of pts <12 y.
In COMMODORE 1, 33 (85%) of 39 pts randomised to crova preferred crova over ecu at W17. Of pts randomised to ecu who switched to crova after W25, 27 (96%) of 28 pts in COMMODORE 1 and 32 (84%) of 38 in COMMODORE 2 preferred crova (Figure 2). Top reasons for crova preference over ecu were: fewer hospital visits required, easier administration, less time needed to administer and better quality of life.
COMMUTE-a and COMMUTE-p are recruiting in 19 and 14 countries, respectively.
Most pts with PNH in COMMODORE 1 and 2 preferred crova to ecu, largely due to faster, easier administration. COMMUTE trials are currently enrolling pts with aHUS.
This abstract was previously submitted to ERA 2024.
